Form 4: Prime Medicine Director and 10% Owner David R. Liu Acquires Additional Shares Under 10b5-1 Plan

David R. Liu, a Director and 10% owner of Prime Medicine, Inc., reported the acquisition of 21,000 shares of common stock at a weighted-average price of $2.5157, effective June 30, 2025, under a Rule 10b5-1 trading plan.

Summary

• David R. Liu, a Director and 10% owner of Prime Medicine, Inc. (PRME), acquired 21,000 shares of the company's common stock.
• The transaction occurred on June 30, 2025, at a weighted-average price of $2.5157 per share.
• Individual share prices for the acquisition ranged from $2.44 to $2.65.
• This acquisition was executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Liu on March 3, 2025.
• Following this transaction, Mr. Liu beneficially owns a total of 20,240,945 shares of Prime Medicine, Inc. common stock.

Sentiment

Score: 8

Explanation: The acquisition of shares by a significant insider (Director and 10% owner) under a pre-planned trading arrangement is a strong positive signal, indicating confidence in the company's future.

Positives

• A significant insider, specifically a Director and 10% owner, acquired additional shares, which typically signals strong confidence in the company's future prospects and valuation.
• The purchase was executed under a pre-arranged Rule 10b5-1 trading plan, indicating a deliberate, long-term investment strategy rather than a reactive market trade.

Future Outlook

The filing itself does not provide a future outlook for the company's performance or strategy, but the insider purchase under a 10b5-1 plan suggests a long-term positive view from a key stakeholder.

Management Comments

• The Reporting Person undertakes to provide full information regarding the number of shares purchased at each separate price within the stated range upon request.

Industry Context

Insider buying, especially by a significant owner and director, can be interpreted as a strong signal of confidence in the company's future prospects within the biotechnology or pharmaceutical industry. It suggests that the insider believes the stock is undervalued or expects positive developments.

Comparison to Industry Standards

• Insider buying activity, particularly by a 10% owner and director, is generally viewed positively across all industries as it indicates management's belief in the company's intrinsic value and future growth.
• While specific comparable companies or projects are not mentioned, such a transaction aligns with patterns where insiders increase their stake when they perceive a disconnect between market valuation and internal prospects.
• The use of a Rule 10b5-1 plan is a standard practice for insiders to execute pre-planned trades, mitigating concerns about trading on material non-public information.

Related Party Transactions

• The reported transaction is an acquisition of common stock by David R. Liu, a Director and 10% owner of Prime Medicine, Inc., which constitutes a related party transaction.

Stakeholder Impact

• Shareholders may view this insider purchase as a positive indicator, potentially increasing investor confidence and demand for the stock.
• The transaction itself does not directly impact employees, customers, suppliers, or creditors, but a positive market reaction could indirectly benefit the company's overall standing.

Key Dates

Recommendation

Keywords

Prime Medicine, PRME, SEC Form 4, Insider Trading, Stock Purchase, David R. Liu, 10b5-1 Plan, Equity Acquisition, Biotechnology, Pharmaceuticals